Abstract:
The present invention relates to a bispecific antibody which is specific to IL-6R and TNF-alpha and a pharmaceutical composition containing the same for preventing and treating autoimmune diseases. The bispecific antibody of the present invention contains (a) an interleukin-6 receptor (IL-6R)-specific monoclonal antibody; and tumor necrosis factor receptor type 2 (TNFR2) proteins which is linked at C-terminal of a constant region of the monoclonal antibody or a fragment containing extracellular region of TNFR2 and is specific to IL-6R and TNF-alpha.
Abstract:
The present invention relates to a pharmaceutical composition containing a vector for treating immune diseases, which expresses bispecific proteins containing anti-IL-6R and TNFR2. The pharmaceutical composition of the present invention relates to a pharmaceutical composition for preventing and treating autoimmune diseases, containing (a) a gene expression cassette; (b) a site-specific recombinant region located at the outside of the gene expression cassette; and (c) a non-viral vector which does not contain a replication origin and a selection marker gene.
Abstract:
The present invention relates to a stem cell therapeutic agent containing a minicircle vector which expresses physiologically active proteins and, more particularly, to stem cells containing a minicircle vector which expresses physiologically active proteins and a pharmaceutical composition and a composition for drug delivery containing the same.
Abstract:
PURPOSE: A composition containing marine minerals and essential inorganic salts for treating rheumatoid arthritis is provided to treat and alleviate rheumatoid arthritis. CONSTITUTION: A composition for treating rheumatoid arthritis contains marine mineral water which is collected underground at a depth of 1100 m at a hot spring of the coastal terrace 92-1, Geumjin-ri, Okgye-myeon, Gangneung-si, Ganwon-do in Korea. The mineral water is a concentrate water containing 200-230 mg/L of potassium, 7000-9500 mg/L of sodium, 1400-1700 mg/L of calcium, 900-1100 mg/L of magnesium, 3-9 mg/L of zinc, 25-35 mg/L of strontium, 200-500 Mg/L of selenium, 65-75 Mg/L of vanadium, 0.5-1.5 Mg/L of germanium, 10-40 Mg/L of manganese, 1-3 Mg/L of cobalt, 600-950 Mg/L of titanium, 3-9 Mg/L of copper, 0.02-0.09 mg/L of lithium, 16000-19500 mg/L of chlorine ion, 1.5-3.0 mg/L of fluorine ion, 40-56 mg/L of bromide ion, 3000-4500 mg/L of sulfate ion, 0.8-1.2 mg/L of boron, and 0.5-1.5 mg/L of silicon dioxide. The composition contains 0.5-50 wt% of the concentrate.
Abstract:
본발명은메트포민및 스타틴의복합제를이용한자가면역질환의예방또는치료용조성물에관한것이다. 본발명에따른메트포민및 스타틴을유효성분으로포함하는복합제인자가면역질환의예방또는치료용약학적조성물은염증성사이토카인의생성을효과적으로억제시킬수 있고, 항체생산 B 세포의생성을저해또는활성을감소시킬수 있으며, 파골세포의분화를억제하고관절파괴를억제하는효과를가지며동맥경화반(Artherosclerotic plaque) 전구세포를형성하는거품세포(Foam cell)의생성억제효과가뛰어나메트포민및 스타틴을유효성분으로하는복합제는자가면역질환의치료제로서매우유용하게활용될수 있다.
Abstract:
The present invention relates to a stem cell therapeutic agent comprising a mini-circle vector expressing a dual-specific protein including anti-IL-6R and TNFR2 and, more specifically, to a stem cell comprising a mini-circle vector expressing a dual-specific protein including anti-IL-6R and TNFR2, and a pharmaceutical composition for treating autoimmune diseases including the same.
Abstract:
The present invention relates to a pharmaceutical composition containing a minicircle vector which expresses tumor necrosis factor receptor type 2 (TNFR2) for treating autoimmune diseases. The pharmaceutical composition of the present invention contains: (a) a gene expression cassette containing a promoter, a gene encoding TNFR2 proteins or a fragment containing extracellular region of TNFR2, and a terminator; b) a site-specific recombinant region located at the outside of the gene expression cassette; and a non-viral vector which does not contain a replication origin and a selection marker gene as active ingredients.